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Abstract
Background: In previous analyses we identified therapy-induced upregulation of the CDK inhibitor
p21CIP/WAF-1 and consequently decreased tumor cell proliferation or loss of Bax as adverse factors for
survival in rectal cancer treated with radiochemotherapy. Here, we address the individual role of p53 and
its transcriptional targets, p21CIP/WAF-1 and Bax, on apoptosis induced by individual components of
multimodal anticancer therapy, i.e. 5-fluorouracil (5-FU), ionising γ-radiation (IR) and heat shock/
hyperthermia.
Methods: We analysed tumor samples 66 patients with rectal carcinoma treated by a neoadjuvant
approach with radiochemotherapy ± heat shock/hyperthermia for the expression and mutation of p53 and
the expression of p21CIP/WAF-1 and Bax. These data were correlated with the tumor response. The
functional relevance of p53, p21CIP/WAF-1 and Bax was investigated in isogeneic HCT116 cell mutants
treated with 5-FU, IR and heat shock.
Results: Rectal carcinoma patients who received an optimal heat shock treatment showed a response
that correlated well with Bax expression (p = 0.018). Local tumor response in the whole cohort was linked
to expression of p21CIP/WAF-1 (p < 0.05), but not p53 expression or mutation. This dichotomy of p53
pathway components regulating response to therapy was confirmed in vitro. In isogeneic HCT116 cell
mutants, loss of Bax but not p53 or p21CIP/WAF-1 resulted in resistance against heat shock. In contrast, loss
of p21CIP/WAF-1 or, to a lesser extent, p53 sensitized predominantly for 5-FU and IR.
Conclusion: These data establish a different impact of p53 pathway components on treatment responses.
While chemotherapy and IR depend primarily on cell cycle control and p21, heat shock depends primarily
on Bax. In contrast, p53 status poorly correlates with response. These analyses therefore provide a
rational approach for dissecting the mode of action of single treatment modalities that may be employed
to circumvent clinically relevant resistance mechanisms in rectal cancer.
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The development of cancer is a multifactorial process that
depends on alterations in both proliferation control and
the cell death machinery. The disruption of these regula-
tory networks, especially of those involved in cell death
signaling, plays a key role in the acquired or constitutive
resistance of malignant tumors to cytotoxic anticancer
therapies [1]. Disruption of components of the p53 sign-
aling pathway is associated with a poor prognosis in gas-
trointestinal tumors [2-6]. Furthermore, in various cell
line models, restoration of defective cell death signaling
sensitized tumor cells to chemotherapy and irradiation [7-
9].
Despite this progress in understanding the molecular
basis of cancer and resistance to anticancer therapy there
is so far only scarce evidence regarding the use of such
molecular parameters in predicting the response to anti-
cancer therapy. Therefore, the aim of this study was to dis-
sect the role of transcription targets of p53, p21CIP/WAF-1
(cell cycle regulation) [10] and Bax (pro-apoptotic multi-
domain Bcl-2 family member) [11], in cell death induced
by the individual components of the multimodal neoad-
juvant therapy applied in treatment of rectal cancer, i.e. 5-
fluoruracil (5-FU), ionising γ-radiation (IR), and heat
shock. These functional analyses were performed in isoge-
neic HCT116 cell mutants. In addition, samples from rec-
tal cancer patients were investigated that were obtained
prior to and after treatment with neoadjuvant radiochem-
otherapy and surgery to define the in vivo and clinical role
of p53, p21CIP/WAF-1 and Bax on the local tumor response.
Data presented here delineate a dichotomy regarding the
impact of these p53 pathway components on cell death
induction by 5-FU, IR and heat shock with p53/p21 regu-
lating response to radiochemotherapy and Bax being
especially critical in response to heat-shock.
Methods
Cell culture
HCT116 colorectal cancer cell line and HCT116 cells car-
rying a targeted knock out for the genes p53 (HCT116
p53-/-) [12], p21CIP/WAF-1 (HCT116 p21-/-) [13] and Bax
(HCT116 Bax -/-) [14] were grown in RPMI (Invitrogen/
Gibco, Karlsruhe, Germany) supplemented with 10%
FCS, 100 U/ml penicillin and 0.1 μg/ml streptomycin.
The genotype was routinely verified by standard immuno-
blotting procedures, as described [15].
Measurement of cell death by flow cytometry
Apoptosis was determined on the single cell level by
measuring the DNA content of individual cells on a FAC-
Scan (Becton Dickinson; Heidelberg, Germany). Briefly,
cells were seeded at a density of 5 × 105 cells in 25 cm2
plastic flasks. After 24 h, cells were exposed to 5-FU
(Sigma, Germany) or IR from a 137Cs source. Heat shock
was applied for 2 hours in 1°C steps. For the application
of heat shock, the culture flasks were put in an incubator
with humidified air and 5% CO2 for two hours. The tem-
perature in the incubator was preset and unchanged dur-
ing the procedure and was controlled by a digital
thermometer before and during the procedure. Cells were
harvested after 72 h. For measurement of apoptosis, the
cellular DNA content was determined following fixation
of the cells, digestion of RNA and staining of the genomic
DNA with propidium iodide (PI) as described [16]. Cells
were measured with logarithmic amplification in the FL-3
channel of a FACScan (Becton Dickinson; Heidelberg,
Germany) equipped with the CELLQuest software. Data
are given in % hypoploidy (sub-G1), which reflects the
percentage of cells displaying apoptotic DNA-fragmenta-
tion.
Patients
In this study, 66 patients with rectal cancer, endosono-
graphically classified as uT3 (n = 58) or uT4 (n = 8) with-
out distant metastases, underwent preoperative
radiochemotherapy alone (RCT n = 35) or combined with
regional hyperthermia (HRCT n = 31). Preoperative radi-
ochemotherapy (RCT) was given with a daily fraction of
1.8 Gy on five days per week for five weeks (total dosis
45Gy) combined with 5-FU (300 mg/m2) plus leucovorin
(50 mg) as a short infusion on the 1st until the 5th and
22nd until the 26th day. Hyperthermia was administered
once a week utilising the annular-phased-array system
BSD-2000 (BSD Medical Corp, Salt Lake City, Utah, USA)
with the SIGMA-60 applicator. Immediately after comple-
tion of the hyperthermia session, the patient was exposed
to the daily dose of irradiation (1.8 Gy). Curative surgery
was attempted 4–6 weeks after completion of preopera-
tive therapy. Patients characteristics and exact treatment
modalities were as published previously [6]. Curative sur-
gery was attempted 4–6 weeks after completion of preop-
erative HRCT, with sphincter sparing surgery in 42 cases
(64%) and abdomino-perineal resection with total mes-
orectal excision in 24 cases (36%). In patients with sus-
pected tumor infiltration in surrounding structures, these
were included by applying an extended monobloc resec-
tion. The detailed study protocol is described in reference
17. In case of R0-resection, the patients received an addi-
tional 4 courses of 5-FU/Leucovorin as adjuvant therapy.
According to the protocol, postoperative treatment was
individualized for the 6 patients with R1 or R2 resection.
Patients were followed for a median of 39.3 months
(range 11.3–83.4 months). Follow-up was done in our
outpatient clinic every 3 months for the first 2 years and
every 6 months thereafter. The institutional board of the
medical faculty Charité Campus Berlin Buch approved
this study. All patients gave their informed consent for
tissue asservation and molecular analyses.Page 2 of 9
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Biopsies of the representative central tumor area of the
rectal cancer were taken (by two investigators (B.R. and
U.S.)) 1 week before and 4–6 weeks after therapy. After
therapy, the tumor biopsy was taken from the specimen
together with the pathologist. The percentage of tumor
regression was determined by the ratio of necrotic or
fibrotic areas to the area of intact cells upon histopatho-
logical examination of the resected material post radio-
chemotherapy. Furthermore, lymphatic and venous vessel
infiltration by tumor cells was evaluated in the resected
specimen after radiochemotherapy. R0-resection was
defined as a tumor free distance to the circumferential
resection margin above 1 mm and was microscopically
assessed by the pathologist.
Definition of response
Response to preoperative treatment was classified accord-
ing to the WHO criteria [17] as described [6] utilising all
imaging modalities (CT, MRI, endosonography) and
endoscopy. Complete remission (CR) was defined after
successful surgical resection by histopathological exami-
nation of the resected specimen for the absence of vital
tumor cells. Partial remission (PR) was defined by a
decrease in the depth of tumor infiltration, as determined
by pathological examination, compared to the prethera-
peutic uT-values (i.e. a reduction of T-category) or in cases
in which the maximum tumor diameter (transverse or
longitudinal) measured by endoscopy or CT/MRI showed
a decrease of at least 50%. Responders in this study were
those patients with a CR or PR, and nonresponders are all
others. According to the defined criteria, 39 patients were
responders and 27 patients were non-responders. The
number of hyperthermia sessions per patient was 4.1 +
1.8. We found a significant relationship for the quality of
hyperthermia, as determined by the parameter cum min
T90 > 40.5°C (> 120 minutes for optimal hyperthermia, <
120 min for suboptimal hyperthermia), and treatment
response (Table 1).
Immunohistochemistry for Bax, p53 and p21CIP/WAF-1
Tumor specimen pre- and posttherapy were investigated
by immunohistochemistry. Specimens of the representa-
tive central tumor area of the rectal cancer were taken 1
week before therapy and 4–6 weeks after neoadjuvant
therapy. For immunohistochemistry, 4 μm slices from
paraffin-embedded tissue were stained applying standard
techniques [2]. The primary antibody was a mouse mon-
oclonal antibody for Bax (clone YTH-2D2, Trevigen,
Gaithersburg, MD, USA; dilution 1:750), a mouse mono-
clonal antibody for p53 (clone DO-7, Dako, Glostrup,
Denmark; dilution 1:75), and a mouse monoclonal anti-
body for p21CIP/WAF-1 (clone 6B6, Pharmingen, San Diego,
CA, USA; dilution 1:75). Analysis of slides was done
blinded, by two observers without knowledge of clinico-
pathological data. Four high power fields (400x) were





ponder n = 
13
p n Responder 
n = 21
Non-Res 
ponder n = 
14
p
Age (year) 61 ± 8* 58 ± 12* n.s. 59 ± 7 57 ± 10 n.s.
Gender male 23 16 7 18 11 7
female 8 2 6 n.s. 17 10 7 n.s.
Infiltration 
depth
uT3 26 13 13 32 19 13




uN0 14 8 6 9 6 3






15 5 10 0.01
radiation 
dose
< 45.94 Gy 2 1 1 1 0 1
≥ 45.94 Gy 29 17 12 n.s. 34 21 13 n.s.
HRCT: radiochemotherapy with heat shock/hyperthermia. RCT: radiochemotherapy without heat shock/hyperthermia. HT: local heat shock/
hyperthermia. LN: lymph node
* mean ± SEM . n.s.: p > 0.05.
1 optimal hyperthermia (temperature-time-interval above pre-defined value): cum min T90 ≥ 40.5°C ≥ 120 min; 2 suboptimal hyperthermia 
(temperature-time-interval below pre-defined value): cum min T90 ≥ 40.5°C < 120 minPage 3 of 9
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steps), and staining intensity (0 to 3). For further analysis,
we used the staining index (STI = product of percentage
positive cells (0–100%) and staining intensity (0, 1, 2 or
3)) as described [4,6]. The "dynamic expression" is calcu-
lated by the post-therapeutic minus the pre-therapeutic
staining index, i.e. a value > 0 denotes an increase in
expression post-therapy, whereas a value < 0 denotes a
decrease (see Fig. 5).
Statistical analysis
For intervariable assessment, the nonparametric U-test or
the χ2-test were used. For longitudinal expression studies
the difference of STI post-therapy and pre-therapy was cal-
culated for paired samples. An increase in expression post-
therapy is indicated by a higher "dynamic" STI compared
to a decrease post-therapy, where the "dynamic" STI is
negative. All tests were 2-sided and p < 0.05 was consid-
ered statistically significant. The analyses were done by the
use of SPSS 10.0 and GraphPad Prism4 for Apple MacIn-
tosh.
Results
Impact of Bax, p53 and p21CIP/WAF-1 knock out in the 
HCT116 model
An increase in p21CIP/WAF-1 expression in rectal carcinoma
treated by preoperative multimodal treatment results in a
significantly reduced disease free survival after multimo-
dal therapy for rectal cancer [6]. This finding suggested a
significant role for p21CIP/WAF-1 in the development of
resistance to therapy in rectal carcinoma. This resistance
mechanism appeared to occur independently from the
tumor suppressor gene p53 and its transcriptional target
Bax. A similar effect connecting p21CIP/WAF-1 and resistance
to chemotherapy was previously demonstrated in the
HCT116 cell line model where the targeted knock-out of
the p21CIP/WAF-1 gene results in sensitivity to DNA damag-
ing chemotherapy [13]. To clarify the roles p53 and the
p53 targets p21 and Bax, we exposed the colorectal cancer
cell line HCT116 to the individual therapeutic modalities
employed in clinical rectal carcinoma therapy: IR, 5-FU
and heat shock. The benefit of this cellular system is that
isogeneic sublines can be tested that carry a gene specific
knock-out for either Bax, p53 of p21CIP/WAF-1 [12-14].
All treatment modalities resulted in the dose dependent
induction of apoptotic cell death after 72 h in the HCT116
wild-type cells. Notably, we observed differential effects of
individual gene knock out on the cell death induction by
the three modalities. Heat shock-induced apoptosis was
entirely Bax-dependent: Bax deficient HCT116 cells were
refractory to apoptosis induced upon treatment with heat
shock at 42°C and 43°C for 2 h (Fig. 1). Thus, disruption
of Bax renders HCT116 cells refractory for induction of
apoptotic cell death following moderate heat shock. In
contrast, 5-FU (Fig. 2) and IR-induced apoptosis (Fig. 3)
were only partially impaired upon absence of Bax.
Loss of p53 resulted in a reduction of apoptosis (Fig. 2)
following exposure to 5-FU that was, however, less pro-
nounced as compared to loss of Bax or disruption of
p21CIP/WAF-1. Notably, IR was not impaired upon loss
of p53. There, loss of p53 led to a moderate increase of
apoptosis induced by irradiation, presumably through the
consequent loss of cell cycle checkpoint control [12]. This
increase was, again, less pronounced as that observed in
the p21-/- HCT116 cells. Finally, loss of p53 resulted in a
moderate reduction of heat shock induced apoptosis (Fig.
1).
Induction of apoptosis by heat shockFig re 1
Induction of apoptosis by heat shock. HCT116 cells 
were exposed to heat shock and cultured for 72 h. 
Grey bars: wild type. Black bars: knock-out mutants. Upper 
panel p53-/-, middle panel p21CIP/WAF-1-/-, lower panel Bax -/-. 
*: p < 0.05, **: p < 0.005.Page 4 of 9
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impressive sensitisation to 5-FU and irradiation-induced
cell death (Fig. 2 and 3). Compared to 5-FU and IR, heat
shock induced apoptosis was, however, not impaired
upon loss of p21CIP/WAF-1 (Fig. 1). This indicates that loss
of cell cycle checkpoint control is important in sensitisa-
tion for irradiation and 5-FU but not for heat shock-
induced apoptosis.
Deregulation of Bax, p53, and p21CIP/WAF-1 and clinical 
response
To corroborate these functional data on the impact of dis-
tinct genotypes on response to cancer therapy, we ana-
lysed a cohort of 66 patients with a defined p53/Bax/p21
status who received 5-FU containing radiochemotherapy
(RCT) alone or in combination with local heat shock
(hyperthermia). Expression profiles were determined in
both specimens obtained at the time of diagnosis (pre-
therapy) and resection material obtained at the time of
surgery, i.e. after pre-operative (neoadjuvant) radiochem-
otherapy (post-therapy). There, patients responding to
RCT in combination with optimal hyperthermia had a sig-
nificantly higher Bax expression level than non-respond-
ers (Bax staining index (STI) in responders: 73 (median,
range 0–180) as compared to 0 (median, range 0–13) in
non-responders (p < 0.02) (Fig. 4). Pre-therapeutic
p21CIP/WAF-1 expression level was correlated with the
response in both the RCT group and the RCT-optimal
hyperthermia group: p21CIP/WAF-1 STI in responders: 25
(median, range 0–150) compared to 2.5 (median, range
0–70) in non-responders (p = 0.03) (RCT group) and
p21CIP/WAF-1 STI in responders: 6 (median, range 0–150)
compared to 2 (median, range 0–3) in non-responders (p
Induction of apoptosis by γ-radiationFig re 3
Induction of apoptosis by γ-radiation. HCT116 cells 
were exposed to IR and cultured for 72 h. Grey bars: 
wild type. Black bars: knock-out mutants. Upper panel p53-/-, 
middle panel p21CIP/WAF-1-/-, lower panel Bax -/-. *: p < 0.05, 
**: p < 0.005.
Induction of apoptosis by 5-flurouracilFig re 2
Induction of apoptosis by 5-flurouracil. HCT116 cells 
were cultured for 72 h in the presence of 5-FU. Grey 
bars: wild type. Black bars: knock-out mutants. Upper panel 
p53-/-, middle panel p21CIP/WAF-1-/-, lower panel Bax -/-. *: p < 
0.05, **: p < 0.005.Page 5 of 9
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In contrast and in analogy to the HCT116 data, no corre-
lation of the p53 expression levels to response state was
seen. The same was true for p53 gene mutations that had
no impact on response to therapy. We identified 8
patients with p53 gene mutations, as described [6]. Of
those, 6 were found in tumors classified as „responder„,
only 2 in tumors classified as „non-responder„ (data not
shown). Thus, there was a trend for better tumor response
to treatment in case of p53 mutation that failed, however,
to reach statistical significance (χ2-test p = 0.56).
Thus, like in the situation of the HCT116 model, loss of
Bax results in resistance to heat shock. Surprisingly, a
response to RCT or HRCT was associated with higher p21
expression. In contrast, p53 deficiency had no impact on
the clinical response to RCT or heat shock plus RCT.
To gain additional information on the kinetic behaviour
of p53 signaling components, we examined tumor sam-
ples again at the time of surgery, i.e. 4–6 weeks after the
completion of neoadjuvant therapy. Due to complete
remission in some patients, the amount of paired samples
(pre-and post-therapy) was reduced to 46 pairs. The post-
therapy expression levels of Bax, p53 or p21CIP/WAF-1 alone
were, however, not significantly different between
responder and non-responder groups. Upon comparison
of pre-versus post-therapeutic expression levels, the subset
of tumors with an increase of p21CIP/WAF-1 expression
showed a significantly reduced disease free survival [6].
We therefore investigated the impact of such dynamic
changes in expression levels for Bax, p53 or p21CIP/WAF-1
Dynamic expression of p53, Bax, p21CIP/WAF-1 and response to therapy in rectal carcinomasFigure 5
Dynamic expression of p53, Bax, p21CIP/WAF-1 and 
response to therapy in rectal carcinomas. Box plot 
analysis of staining indices for p53, Bax and p21CIP/WAF-1 
(post-therapy staining index (STI) – pre-therapy STI. White 
bars: Responders (R), grey bars: Non-responders (NonR). 
RCT: responders n = 14, non-responders = 12, HRCT: 
responders n = 11, non-responders = 9, Optimal hyperther-
mia: responders n = 8, non-responders = 3.
Pre-therapeutic expression of p53, Bax, p21CIP/WAF-1 and response to therapy in rectal carcinomasFigur  4
Pre-therapeutic expression of p53, Bax, p21CIP/WAF-1 
and response to therapy in rectal carcinomas. Box 
plot analysis of staining indices (STI) for p53, Bax and p21CIP/
WAF-1. White bars: Responders (R), grey bars: Non-respond-
ers (NonR), RCT: radiochemotherapy. (responders n = 21, 
non-responders n = 14), HRCT: hyperthermic radiochemo-
therapy (responders n = 18, non-responders n = 13), optimal 
hyperthermia: subgroup of HRCT, definition see text 
(responders n = 13, non-responders n = 3).Page 6 of 9
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trend for higher p53 and Bax levels in the optimal hyper-
thermia/heat shock group, we found the dynamic increase
of p21CIP/WAF-1 expression in the RCT-treated group to be
associated with a failure to respond to therapy. The
median dynamic p21 STI for responders was lower (-
28.25 (range -148.4 – 32.5; n = 14) than for non-respond-
ers (-1.75 (range -69 – 5.5); n = 12; p = 0.057) (Fig. 5).
Hence, tumors of patients who responded to RCT exhib-
ited a strong decrease of p21CIP/WAF-1 expression post-ther-
apy. This finding is in line with both the data from the
HCT116 model and the observation that the dynamic
increase of p21CIP/WAF-1 as observed in paired tumor sam-
ples is related to a highly reduced disease free survival, i.e.
a failure to respond to clinical cancer therapy [6].
Discussion
Aim of this study was to investigate the p53 and to define
the impact of individual gene defects in p53 and the tran-
scriptional p53 targets Bax and p21CIP/WAF-1. To this end,
we investigated HCT116 mutants derived from targeted
gene knock-out of p53, p21CIP/WAF-1 or Bax and validated
the relevance of these data by the use of clinical samples
of rectal carcinoma.
In the present study we show the relevance of the cyclin
dependent kinase inhibitor p21CIP/WAF-1 for apoptosis sen-
sitivity towards 5-Fuand IR in vitro and for local tumor
control in vivo. In HCT116 wild type and HCT116 p21-/-
knock-out cells, we found a strong correlation between
disruption of p21CIP/WAF-1 and in vitro sensitivity towards
5-FU and, to a lesser extent, towards IR-induced cell death.
The lack of p21CIP/WAF-1 in tumor cells was described to
lead to an uncoupling of S- and M-phase and to cell death
in consequence of a mitotic catastrophe upon DNA dam-
age [13]. Conversely, sensitivity to IR in tumor cells is
higher when the expression of p21CIP/WAF-1 is blocked
[18]. Our in vitro data are in accordance with these find-
ings. A striking finding is the strong dependency of 5-FU
induced cell death on p21CIP/WAF-1. To our knowledge, this
is the first description of this effect. Furthermore, the in
vitro experiments show that heat-shock induced apoptosis
does not rely on p21CIP/WAF-1. This is a strong cell biologi-
cal argument for the combination of different treatment
modalities, i.e. the addition of hyperthermia (p21CIP/WAF-
1-independent) to radiochemotherapy (p21CIP/WAF-1-
dependent). In fact, these cell biological data are in
accordance with the impact of p21CIP/WAF-1 expression in
the clinical tumor samples.
There, tumors with positive pre-therapeutic p21CIP/WAF-1
expression showed a better local tumor response. This is
in line with the trend for longer survival in p21CIP/WAF-1
expressing tumors in our previous study [6] and with data
from ovarian cancer [19], rectal cancer [20,21], head and
neck cancer [22], or pancreatic cancer [23]. As p21CIP/WAF-
1 is a direct transcriptional target of p53, it can be argued
that therapy-naive tumors expressing p21CIP/WAF-1 have an
intact p53-regulatory pathway of cell cycle arrest, senes-
cence and apoptosis. In fact, up-regulation of p21CIP/WAF-1
may serve as a read-out for functional integrity of the p53
gene in malignant cells [2,24-26]. Nevertheless, a different
picture is obtained when tumors are investigated not
hours, but 4 to 6 weeks post-therapy: the persistence of
highly p21CIP/WAF-1-expressing tumor cells 4 to 6 weeks
after the completion of a neoadjuvant multimodal ther-
apy is an adverse effect for survival [6]. It is therefore likely
that this persistent increase of the amount of p21CIP/WAF-1
expressing tumor cells is related to a selection process of
resistant tumor cells by the neoadjuvant therapy that
results in a stable increase of the p21CIP/WAF-1 protein.
Notably, we recently observed that cell cycle arrest via
upregulation of p21CIP/WAF-1 impedes IR-induced activa-
tion of a caspase-3 dependent apoptotic program [27].
This behaviour is mimicked in the HCT116 p21CIP/WAF-1
k.o. model. There, p21CIP/WAF-1 mediates resistance to radi-
ochemotherapy but not heat-shock induced cell death.
Similarly to p21CIP/WAF-1, the differential effect of the pro-
apoptotic Bax on sensitivity to radiochemotherapy and
Model of individual genes (p53, p21CIP/WAF-1 and Bax) showing differential impact on the cell death inductio  by 5-FU, IR orheat sh ckFigure 6
Model of individual genes (p53, p21CIP/WAF-1 and Bax) showing 
differential impact on the cell death induction by 5-FU, IR or 
heat shock.Page 7 of 9
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combination of various treatment modalieties. Bax plays
a key role in activating the mitochondrial apoptosis path-
way upon various death stimuli. In cell line models, the
presence of Bax was associated with increased apoptosis
sensitivity to TRAIL, 5-FU [8], ceramide (von Haefen et al,
2002), the toxin calicheamicin [28] and IR [27] or the
BH3-only protein Nbk/Bik [29], whereas other stimuli
were Bax-independent [26,30]. In clinical samples, we
found an intact p53/Bax-pathway to be associated with
better survival [2-5]. Our present in vitro data therefore
confirm that tumor cells without Bax are less sensitive to
chemotherapy and IR. An even stronger impact of Bax loss
was observed in heat shock induced apoptosis. Heat
shock up to 43°C triggered apoptotic death in the Bax
wild type HCT116 cells whereas Bax-/- HCT116 cells were
refractory to heat shock induced apoptosis. This is in line
with a previous finding of our group showing that the
enforced overexpression of Bak or Nbk/Bik sensitises for
heat shock [15]. Most interestingly, the clinical data sup-
port these in vitro data strongly. Optimal hyperthermia
was associated with a good tumor response only when
tumors expressed high amounts of Bax whereas Bax-defi-
cient tumors failed to respond to heat shock.
When compared to p21 and Bax, the p53 gene exhibited
only a weak influence on sensitivity towards chemother-
apy with 5-FU, irradiation and none towards heat shock.
These in vitro data are in line with the clinical findings.
Hence, up to now there is no convincing evidence that
loss of p53 or mutational inactivation of p53 represents a
negative prognostic factor or results in clinical resistance
in carcinomas. This strengthens the assumption that p53
bypasses do exist and that essential p53 downstream
effectors can be regulated by other means in case p53 fails.
Conclusion
In conclusion, our data demonstrate that a systematic
genetic and functional dissection of apoptosis and cell
cycle regulatory pathways in tumor cells reveals differen-
tial cellular effects in various antitumor treatment modal-
ities that have a direct impact on cancer therapy. A model
of the differential sensitivities to 5-FU, γ-irradiation and
heat shock with regard to Bax, p53 and p21CIP/WAF-1 is out-
lined in figure 6. Notably, we demonstrated the relevance
of our data in both clinical samples and in genetically
defined, syngeneic HCT116 cells. These findings therefore
provide an evidence-based cell biological model for the
usefulness of combining heat shock/hyperthermia (which
seems to be p21CIP/WAF-1 and p53-independent, but Bax-
dependent) with radiochemotherapy (which is p21CIP/
WAF-1-dependent). Inclusion of additional pathway com-
ponents and treatment modalities is, however, warranted
towards the aim of a further individualisation of cancer
therapy based on a molecular tumor profile.
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